ArticleInternational journal of nanomedicine2025
Formulation and Characterization of
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop a nanosuspension formulation of Methods: Nanosuspensions were prepared using an antisolvent technique, with Tween 80 as the stabilizing agent. The formulations were characterized by particle size analysis, zeta potential, and polydispersity index (PDI) to evaluate their stability and uniformity. Transmission electron microscopy (TEM) confirmed nanoparticle formation, and stability assessments were conducted over 28 days under refrigerated conditions. In vitro release studies were conducted to assess sustained drug release, and antioxidant activity and lipid-lowering efficacy were compared to those of simvastatin. Results: The NS-Sa-4:1 formulation exhibited optimal properties, including an average particle size of 12.9 nm, zeta potential of -12.5 mV, and PDI of 0.317, indicating a stable and uniform nanosuspension. TEM images revealed well-dispersed nanoparticles, and stability tests demonstrated the retention of these properties for up to 28 days. In vitro release studies showed sustained drug release, with 92.51% released within 24 h, surpassing the crude extract and other formulations. NS-Sa-4:1 also demonstrated enhanced antioxidant activity and significant lipid-lowering effects compared with simvastatin. Conclusion: The nanosuspension of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.